Market Overview

UPDATE: Sterne Agee Downgrades Greenway Medical Technologies to Underperform on Multiple Compression

Related GWAY
Market Wrap For Tuesday, September 24: Markets Go Parabolic
Mid-Afternoon Market Update: Carnival Sinks on Weak Guidance; Markets Go Into The Red

Sterne Agee reduced its rating on Greenway Medical Technologies (NYSE: GWAY) from Neutral to Underperform and lowered its price target from $15 to $14.

Sterne Agee said, "Consensus CY13 EBITDA estimate has dropped 8% while the EV/EBITDA multiple increased by ~4 points (17%) over the past month (Exhibit 2). GWAY has the second highest EV/EBITDA multiple among peers. Without a meaningful upward revision to EBITDA guidance, we do not believe this multiple trajectory is sustainable. The company currently forecasts adjusted EBITDA of $19.3-23.4 million for FY13. Our estimate is at the midpoint of the range."

Greenway Medical Technologies closed at $17.75 on Friday.

Latest Ratings for GWAY

Sep 2013KeyBancDowngradesBuyHold
Sep 2013Raymond JamesDowngradesStrong BuyMarket Perform
Sep 2013William BlairDowngradesOutperformMarket Perform

View More Analyst Ratings for GWAY
View the Latest Analyst Ratings

Posted-In: Sterne AgeeAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (GWAY)

View Comments and Join the Discussion!